alexa fluor 700 labeled mouse anti human epha2 (R&D Systems)
Structured Review

Alexa Fluor 700 Labeled Mouse Anti Human Epha2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alexa+fluor+700+labeled+mouse+anti+human+epha2/pmc08366541-57-5-12?v=R%26D+Systems
Average 92 stars, based on 1 article reviews
Images
1) Product Images from "Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1"
Article Title: Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1
Journal: Oncoimmunology
doi: 10.1080/2162402X.2021.1960728
Figure Legend Snippet: Developing EphA2-Specific CAR-T Cells (a) Schematic diagram of two different chimeric antigen receptors (CARs) targeting EphA2. It consists of EphA2 scFv, the hinge, transmembrane (TM) region of CD28, CD28 and 4–1BB signaling domain, and human CD3ζ chain. (b) CAR-T cells were subjected to immunoblotting to detect the expression of full-length EphA2-CARs by using CD3ζ antibody. (c) Different EphA2-CAR-T cells were labeled with CFSE and then co-cultured with U251 cells for 72 h. The extent of T cell proliferation is reflected by the loss of incorporated CFSE. (d) CAR-T cells were co-cultured with U251 cells for 15 days at an E:T ratio of 2:1. T cells were stimulated every three days with fresh U215 cells, and T cells were counted before the addition of U251 cells. Results were analyzed by student’s t-test, and a p < .05 was considered significant. *p < .05, ***p < .001. SD, splice donor; SA, splice acceptor
Techniques Used: Western Blot, Expressing, Labeling, Cell Culture
Figure Legend Snippet: Comparison of antitumor effects of different EphA2 CAR-T cells In vitro. NT or EphA2 CAR-T cells were co-cultured with different target cells at different E:T ratios (1:1, 2.5:1, 5:1, and 10:1) for 24 h. (a) The cell lysis rate was quantified by examining the luciferase activity. (b) The supernatants were collected to evaluate IFN-γ levels by ELISA (E:T = 10:1). (c) Continuous graphical output of cell index values up to the 50 h time point was monitored using the xCELLigence impedance system. Results were analyzed by one-way ANOVA, and statistical significance was set at *p < .05, **P < .01, ***p < .001
Techniques Used: Comparison, In Vitro, Cell Culture, Lysis, Luciferase, Activity Assay, Enzyme-linked Immunosorbent Assay
Figure Legend Snippet: Comparison of antitumor effects of different EphA2 CAR-T cells in xenograft mouse models. (a) 5 × 10 6 eGFP-Luc-U251 cells were injected subcutaneously into the left flank of 6–8 week-old female NOD-SCID mice. Ten days after injection, the tumor bearing mice were treated with 3 × 10 7 EphA2 CAR T cells through direct injection into the tumor, with un-transduced T cells (NT) as control. The tumor growth was monitored using the IVIS system with a tumor diameter of 2 cm as the endpoint. Quantitative bioluminescence (radiance = photons/cm 2 /sr) imaging data for all mice are shown. Overall survival of mice with GBM xenografts was measured using the Kaplan–Meier method, with Cox proportional hazard regression analysis for group comparison. A p -value less than 0.05 was considered significant. (b) Six to eight week-old NOD-SCID mice were anesthetized and then 2 × 10 5 cells were injected into the left striatum through a burr hole in the skull. Two weeks after tumor cells injection, 3 × 10 7 CAR-T cells were injected through the tail vein. Thereafter, the tumor growth was monitored using in vivo imaging system IVIS. Quantitative bioluminescence (radiance = photons/cm 2 /sr) imaging data for all mice are shown. Overall survival of mice with GBM xenografts were measured using the Kaplan–Meier method, with Cox proportional hazard regression analysis for group comparison. A p -value less than 0.05 was considered significant
Techniques Used: Comparison, Injection, Control, Imaging, In Vivo Imaging
Figure Legend Snippet: Low IFN-γ and CXCL8 levels relate to better anti-tumor activity in EphA2-CAR-T cells. EphA2 CAR-T cells before or after co-culture with GBM cells were subjected to RT-qPCR to examine the expression of IFN-γ, CXCL8, IL-21, CXCR1, and CXCR2. Results were analyzed by one-way ANOVA and statistical significance was set at p < .05. *p < .05, **P < .01
Techniques Used: Activity Assay, Co-Culture Assay, Quantitative RT-PCR, Expressing
Figure Legend Snippet: EphA2-b-CAR-T cells induced upregulated PD-L1 expression in GBM cells. (a) GBM cells were co-cultured with CAR-T cells at an E:T ratio of 2:1 for 30 min and 4 h. The GBM cells were then subjected to RT-qPCR to determine the PD-L1 level. (b) The PD-L1 and Ki-67 levels in the tumors from CAR-T cells treated mice were detected by immunohistochemistry. The positive signal was quantified by Image J. Results were analyzed One-way ANOVA and statistical significance was set at p < .05. *p < .05, **P < .01, ***p < .001
Techniques Used: Expressing, Cell Culture, Quantitative RT-PCR, Immunohistochemistry
Figure Legend Snippet: EphA2-b-CAR-T treatment combined with PD1 blockade exhibited enhanced antitumor activity. U251 and U373 cells were transiently transfected with one of the siRNAs to knock down the expression of IFNGR1, IFNGR2 or PG-L1 separately (a and b), and then the cells were subjected to an in vitro killing assay at an E:T = 1:1. The cell lysis rates were determined by detecting luciferase activity (c). NOD-SCID mice were injected subcutaneously with 1 × 10 7 U251.eGFP.Luc cells to construct a xenograft mouse model. Five days post-tumor xenograft, mice were treated with a total of 3 × 10 7 CAR-T cells or non-transduced control T cells peritumorally, followed by peritumoral (p.t.) administration of 200 μg PD1 antibody. On day 13, the mice were administered a second dose of PD1antibody, and tumor growth was monitored using IVIS (D, E, and F)
Techniques Used: Activity Assay, Transfection, Knockdown, Expressing, In Vitro, Lysis, Luciferase, Injection, Construct, Control
Figure Legend Snippet: Experiment workflow and proposed model of better anti-tumor efficacy after EphA2-a-CAR-T cells treatment
Techniques Used:
Figure Legend Snippet:
Techniques Used: Cell Analysis, Variant Assay